Artal Group S.A. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001053906
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 109 positions · Total reported value $3.83B · Top-10 concentration 78.5% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 33.3% · 1 new · 0 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q2 2024 13F filing, Artal Group S.A. disclosed 109 equity positions with a combined reported value of $3.83B. The filing implies a focused portfolio: its ten largest positions account for 78.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Consumer Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were CAVA ($2.18B), LXRX ($294.17M), SRRK ($93.79M). By sector, the heaviest allocations are Consumer Discretionary 57.6%, Health Care 29.9%. Versus the prior quarter, allocation shifted toward Consumer Discretionary (+8.4pp), Technology (+0.5pp) and away from Other (-3.3pp), Health Care (-5.6pp).
Versus the prior quarter, Artal Group S.A. opened 1 new positions, trimmed 0 and fully exited 0, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 68% of names.
The largest new positions opened in Q2 2024 were RNAM ($26.78M), CGEM ($18.45M), ASND ($13.79M).
Of the 8 positions fully exited versus the prior quarter, the largest were MDGL ($29.51M), XBI ($23.72M), VKTX ($20.82M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- RNAM AVIDITY BIOSCIENCES INC · $26.78M
- CGEM CULLINAN THERAPEUTICS INC · $18.45M
- ASND ASCENDIS PHARMA A/S · $13.79M
- BHVN BIOHAVEN LTD · $10.65M
- RAPP RAPPORT THERAPEUTICS INC · $8.14M
- IOVA IOVANCE BIOTHERAPEUTICS INC · $8.11M
- MNMD MIND MEDICINE MINDMED INC · $7.27M
- ADCT ADC THERAPEUTICS SA · $3.22M
Fully Exited (vs previous quarter)
- MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $29.51M
- XBI SPDR SERIES TRUST · prev qtr: $23.72M
- VKTX VIKING THERAPEUTICS INC · prev qtr: $20.82M
- ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $16.09M
- ATXS ASTRIA THERAPEUTICS INC · prev qtr: $12.45M
- FOLD AMICUS THERAPEUTICS INC · prev qtr: $11.92M
- CLDX CELLDEX THERAPEUTICS INC NEW · prev qtr: $10.62M
- APGE APOGEE THERAPEUTICS INC · prev qtr: $10.13M
Insider Transactions (Form 4)
Latest Artal Group S.A. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-15 | Sell | CAVA GROUP, INC. | 3,000,000 | $90.30 | SEC filing |
| 2026-04-30 | Opt exercise | LEXICON PHARMACEUTICALS, INC. | 20,421,735 | — | SEC filing |
Fund Profile
Artal Group S.A. is an SEC-registered 13F filer. As of Q2 2026 it reported 2 US equity positions with a combined value of $931.12M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 2 positions · $931.12M reported value (Q2 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: CAVA (CAVA GROUP INC) at 54.9%
- Average position size: $465.56M
Sector Tilt
- Consumer Discretionary 54.9%
- Health Care 45.1%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 1 added, 1 reduced
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
23.51M | $2.18B | 56.98% | Reduce | |
| 2 |
|
175.10M | $294.17M | 7.69% | Add | |
| 3 |
|
11.26M | $93.79M | 2.45% | Hold | |
| 4 |
|
3.01M | $89.72M | 2.35% | Reduce | |
| 5 |
|
2.53M | $86.06M | 2.25% | Add | |
| 6 |
|
1.47M | $56.28M | 1.47% | Add | |
| 7 |
|
1.52M | $53.53M | 1.40% | Hold | |
| 8 |
|
2.78M | $52.81M | 1.38% | Hold | |
| 9 |
|
1.31M | $49.46M | 1.29% | Reduce | |
| 10 |
|
1.07M | $47.75M | 1.25% | Reduce | |
| 11 |
|
760.36K | $44.99M | 1.18% | Add | |
| 12 |
|
303.37K | $43.28M | 1.13% | Reduce | |
| 13 |
|
1.02M | $39.42M | 1.03% | Reduce | |
| 14 |
|
1.82M | $37.47M | 0.98% | Reduce | |
| 15 |
|
915.97K | $33.14M | 0.87% | Add | |
| 16 |
|
2.82M | $27.76M | 0.73% | Reduce | |
| 17 |
|
494.42K | $26.79M | 0.70% | Reduce | |
| 18 |
|
655.55K | $26.78M | 0.70% | New | |
| 19 |
|
1.00M | $25.99M | 0.68% | Add | |
| 20 |
|
3.33M | $22.88M | 0.60% | Add | |
| 21 |
|
4.57M | $22.79M | 0.60% | Add | |
| 22 |
|
9.63M | $22.73M | 0.59% | Add | |
| 23 |
|
2.52M | $21.62M | 0.56% | Add | |
| 24 |
|
1.00M | $20.67M | 0.54% | Hold | |
| 25 |
|
2.11M | $19.08M | 0.50% | Add | |
| 26 |
|
1.06M | $18.45M | 0.48% | New | |
| 27 |
|
800.00K | $15.37M | 0.40% | Hold | |
| 28 |
|
381.55K | $14.88M | 0.39% | Add | |
| 29 |
|
811.72K | $14.62M | 0.38% | Hold | |
| 30 |
|
2.50M | $14.18M | 0.37% | Hold | |
| 31 |
|
413.07K | $13.99M | 0.37% | Reduce | |
| 32 |
|
101.10K | $13.79M | 0.36% | New | |
| 33 |
|
775.00K | $12.98M | 0.34% | Reduce | |
| 34 |
|
2.51M | $12.93M | 0.34% | Hold | |
| 35 |
|
502.90K | $11.68M | 0.30% | Hold | |
| 36 |
|
275.00K | $11.30M | 0.29% | Add | |
| 37 |
|
306.70K | $10.65M | 0.28% | New | |
| 38 |
|
4.35M | $9.75M | 0.26% | Add | |
| 39 |
|
603.43K | $9.68M | 0.25% | Reduce | |
| 40 |
|
2.02M | $8.91M | 0.23% | Reduce | |
| 41 |
|
203.00K | $8.50M | 0.22% | Add | |
| 42 |
|
304.55K | $8.23M | 0.21% | Reduce | |
| 43 |
|
350.00K | $8.14M | 0.21% | New | |
| 44 |
|
1.01M | $8.11M | 0.21% | New | |
| 45 |
|
2.83M | $7.98M | 0.21% | Hold | |
| 46 |
|
4.75M | $7.98M | 0.21% | Hold | |
| 47 |
|
1.83M | $7.31M | 0.19% | Add | |
| 48 |
|
1.01M | $7.27M | 0.19% | New | |
| 49 |
|
97.50K | $6.96M | 0.18% | Reduce | |
| 50 |
|
45.50K | $6.05M | 0.16% | Reduce | |
FAQ
What did Artal Group S.A. buy in 2024-Q2?
In its 2024-Q2 13F filing, Artal Group S.A. reported 109 equity positions worth $3.83B in aggregate; its largest disclosed positions were CAVA ($2.18B), LXRX ($294.17M), SRRK ($93.79M).
How large is Artal Group S.A.'s portfolio?
Artal Group S.A. reported $3.83B of long equity holdings across 109 positions as of 2024-Q2. Top-10 holdings account for 78.5% of reported value.
What is Artal Group S.A.'s investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Consumer Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.